NASDAQ: KLRA
Kailera Therapeutics Inc Stock Ownership - Who owns Kailera Therapeutics?

Insider buying vs selling

Have Kailera Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Ronald C. Renaud Jr.CEO President2026-06-0938,094$5.25
$199.99kBuy
Bain Capital Investors LLC10% Owner2026-04-208,398,438$16.00
$134.38MBuy
Bain Capital Life Sciences Investors LLC10% Owner2026-04-201,562,500$16.00
$25.00MBuy
Andrew T. KaplanDirector2026-04-208,398,438$16.00
$134.38MBuy
Adam KoppelDirector2026-04-201,562,500$16.00
$25.00MBuy
Rtw Investments LP10% Owner2026-04-20500,000$16.00
$8.00MBuy

1 of 1

KLRA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KLRA insiders and whales buy or sell their stock.

KLRA Shareholders

What type of owners hold Kailera Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Bain Capital Investors LLC20.26%26,255,581$483.37MInsider
Andrew T. Kaplan20.26%26,255,581$483.37MInsider
Bain Capital Life Sciences Investors LLC17.43%22,583,268$415.76MInsider
Adam Koppel17.43%22,583,268$415.76MInsider
Rtw Investments LP8.32%10,776,820$198.40MInsider
Jiangsu Hengrui Pharmaceuticals Co Ltd1.57%2,034,134$37.45MInsider
Ronald C. Renaud Jr.0.03%38,094$701.31kInsider

1 of 1

KLRA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KLRA0.00%85.31%Net BuyingNet Buying
ZLAB2.51%1.78%Net BuyingNet Buying
IOVA19.87%80.13%Net SellingNet Selling
COAG0.00%20.31%Net BuyingNet Buying
NUVB58.01%41.99%Net BuyingNet Buying

Kailera Therapeutics Stock Ownership FAQ

Who owns Kailera Therapeutics?

Kailera Therapeutics (NASDAQ: KLRA) is owned by 0.00% institutional shareholders, 85.31% Kailera Therapeutics insiders, and 14.69% retail investors. Bain Capital Investors LLC is the largest individual Kailera Therapeutics shareholder, owning 26.26M shares representing 20.26% of the company. Bain Capital Investors LLC's Kailera Therapeutics shares are currently valued at $467.09M.

If you're new to stock investing, here's how to buy Kailera Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.